Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings

Hiroyuki Katayama, Sophie Paczesny, Ross Prentice, Aaron Aragaki, Vitor M. Faca, Sharon J. Pitteri, Qing Zhang, Hong Wang, Melissa Silva, Jacob Kennedy, Jacques Rossouw, Rebecca Jackson, Judith Hsia, Rowan Chlebowski, JoAnn Manson, Samir Hanash

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The availability of serum collections from the Women's Health Initiative (WHI) conjugated equine estrogens (CEE) randomized controlled trial provides an opportunity to test the potential of in-depth quantitative proteomics to uncover changes in the serum proteome related to CEE and to assess their relevance to trial findings, including elevations in the risk of stroke and venous thromboembolism and a reduction in fractures. Methods: Five independent large scale quantitative proteomics analyses were performed, each comparing a set of pooled serum samples collected from 10 subjects, 1 year following initiation of CEE at 0.625 mg/d, relative to their baseline pool. A subset of proteins that exhibited increased levels with CEE by quantitative proteomics was selected for validation studies. Results: Of 611 proteins quantified based on differential stable isotope labeling, the levels of 116 (19%) were changed after 1 year of CEE (nominal P <0.05), while 64 of these had estimated false discovery rates

Original languageEnglish (US)
Article numbergm47
JournalGenome Medicine
Volume1
Issue number4
DOIs
StatePublished - Apr 29 2009
Externally publishedYes

Fingerprint

Conjugated (USP) Estrogens
Women's Health
Proteomics
Serum
Isotope Labeling
Fracture Fixation
Validation Studies
Venous Thromboembolism
Proteome
Proteins
Randomized Controlled Trials
Stroke

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. / Katayama, Hiroyuki; Paczesny, Sophie; Prentice, Ross; Aragaki, Aaron; Faca, Vitor M.; Pitteri, Sharon J.; Zhang, Qing; Wang, Hong; Silva, Melissa; Kennedy, Jacob; Rossouw, Jacques; Jackson, Rebecca; Hsia, Judith; Chlebowski, Rowan; Manson, JoAnn; Hanash, Samir.

In: Genome Medicine, Vol. 1, No. 4, gm47, 29.04.2009.

Research output: Contribution to journalArticle

Katayama, H, Paczesny, S, Prentice, R, Aragaki, A, Faca, VM, Pitteri, SJ, Zhang, Q, Wang, H, Silva, M, Kennedy, J, Rossouw, J, Jackson, R, Hsia, J, Chlebowski, R, Manson, J & Hanash, S 2009, 'Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings', Genome Medicine, vol. 1, no. 4, gm47. https://doi.org/10.1186/gm47
Katayama, Hiroyuki ; Paczesny, Sophie ; Prentice, Ross ; Aragaki, Aaron ; Faca, Vitor M. ; Pitteri, Sharon J. ; Zhang, Qing ; Wang, Hong ; Silva, Melissa ; Kennedy, Jacob ; Rossouw, Jacques ; Jackson, Rebecca ; Hsia, Judith ; Chlebowski, Rowan ; Manson, JoAnn ; Hanash, Samir. / Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. In: Genome Medicine. 2009 ; Vol. 1, No. 4.
@article{d36e26069e7444f4a4711be36bc3db1b,
title = "Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings",
abstract = "Background: The availability of serum collections from the Women's Health Initiative (WHI) conjugated equine estrogens (CEE) randomized controlled trial provides an opportunity to test the potential of in-depth quantitative proteomics to uncover changes in the serum proteome related to CEE and to assess their relevance to trial findings, including elevations in the risk of stroke and venous thromboembolism and a reduction in fractures. Methods: Five independent large scale quantitative proteomics analyses were performed, each comparing a set of pooled serum samples collected from 10 subjects, 1 year following initiation of CEE at 0.625 mg/d, relative to their baseline pool. A subset of proteins that exhibited increased levels with CEE by quantitative proteomics was selected for validation studies. Results: Of 611 proteins quantified based on differential stable isotope labeling, the levels of 116 (19{\%}) were changed after 1 year of CEE (nominal P <0.05), while 64 of these had estimated false discovery rates",
author = "Hiroyuki Katayama and Sophie Paczesny and Ross Prentice and Aaron Aragaki and Faca, {Vitor M.} and Pitteri, {Sharon J.} and Qing Zhang and Hong Wang and Melissa Silva and Jacob Kennedy and Jacques Rossouw and Rebecca Jackson and Judith Hsia and Rowan Chlebowski and JoAnn Manson and Samir Hanash",
year = "2009",
month = "4",
day = "29",
doi = "10.1186/gm47",
language = "English (US)",
volume = "1",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "4",

}

TY - JOUR

T1 - Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings

AU - Katayama, Hiroyuki

AU - Paczesny, Sophie

AU - Prentice, Ross

AU - Aragaki, Aaron

AU - Faca, Vitor M.

AU - Pitteri, Sharon J.

AU - Zhang, Qing

AU - Wang, Hong

AU - Silva, Melissa

AU - Kennedy, Jacob

AU - Rossouw, Jacques

AU - Jackson, Rebecca

AU - Hsia, Judith

AU - Chlebowski, Rowan

AU - Manson, JoAnn

AU - Hanash, Samir

PY - 2009/4/29

Y1 - 2009/4/29

N2 - Background: The availability of serum collections from the Women's Health Initiative (WHI) conjugated equine estrogens (CEE) randomized controlled trial provides an opportunity to test the potential of in-depth quantitative proteomics to uncover changes in the serum proteome related to CEE and to assess their relevance to trial findings, including elevations in the risk of stroke and venous thromboembolism and a reduction in fractures. Methods: Five independent large scale quantitative proteomics analyses were performed, each comparing a set of pooled serum samples collected from 10 subjects, 1 year following initiation of CEE at 0.625 mg/d, relative to their baseline pool. A subset of proteins that exhibited increased levels with CEE by quantitative proteomics was selected for validation studies. Results: Of 611 proteins quantified based on differential stable isotope labeling, the levels of 116 (19%) were changed after 1 year of CEE (nominal P <0.05), while 64 of these had estimated false discovery rates

AB - Background: The availability of serum collections from the Women's Health Initiative (WHI) conjugated equine estrogens (CEE) randomized controlled trial provides an opportunity to test the potential of in-depth quantitative proteomics to uncover changes in the serum proteome related to CEE and to assess their relevance to trial findings, including elevations in the risk of stroke and venous thromboembolism and a reduction in fractures. Methods: Five independent large scale quantitative proteomics analyses were performed, each comparing a set of pooled serum samples collected from 10 subjects, 1 year following initiation of CEE at 0.625 mg/d, relative to their baseline pool. A subset of proteins that exhibited increased levels with CEE by quantitative proteomics was selected for validation studies. Results: Of 611 proteins quantified based on differential stable isotope labeling, the levels of 116 (19%) were changed after 1 year of CEE (nominal P <0.05), while 64 of these had estimated false discovery rates

UR - http://www.scopus.com/inward/record.url?scp=77950850143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950850143&partnerID=8YFLogxK

U2 - 10.1186/gm47

DO - 10.1186/gm47

M3 - Article

C2 - 19402886

AN - SCOPUS:77950850143

VL - 1

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 4

M1 - gm47

ER -